动物造模,诱发性炎性肠病 z-bio 2022-03-25 810

　　Objective To explore the therapeutic effect of anti-complement 5a receptor (C5aR) antibody combined with allicin on inflammatory bowel disease (IBD) in rats.

　　Methods Eighty male IBD rats induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) were randomly divided into 4 groups: model control group, anti-C5aR antibody treatment group, allicin treatment group, anti-C5aR antibody treatment group Combined with allicin treatment group; the other 20 male rats were normal control group. Before and 14 days after drug administration, the changes of body weight and survival rate of rats were counted, and the levels of interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) in serum of rats were detected. observation and pathological scoring.

　　Results The body weight and survival rate of the rats in the anti-C5aR antibody combined with allicin treatment group were higher than those in the other treatment groups, and the expression levels of inflammatory factors II-6 and TNF-α in the serum of the rats showed a significant regression trend; colon tissue The pathological score also showed that the effect of the combined treatment group was significantly better than that of the other treatment groups (P<0.05).

　　Conclusion Anti-C5aR antibody combined with allicin is an effective regimen for the treatment of TNBS-induced IBD in rats, and its efficacy is better than that of anti-C5aR antibody or allicin alone.